全文获取类型
收费全文 | 751篇 |
免费 | 35篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 41篇 |
妇产科学 | 1篇 |
基础医学 | 36篇 |
口腔科学 | 25篇 |
临床医学 | 105篇 |
内科学 | 378篇 |
皮肤病学 | 2篇 |
神经病学 | 11篇 |
特种医学 | 97篇 |
外科学 | 64篇 |
综合类 | 24篇 |
预防医学 | 6篇 |
药学 | 46篇 |
中国医学 | 2篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 9篇 |
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 3篇 |
2019年 | 4篇 |
2018年 | 14篇 |
2017年 | 9篇 |
2016年 | 9篇 |
2015年 | 7篇 |
2014年 | 17篇 |
2013年 | 20篇 |
2012年 | 28篇 |
2011年 | 31篇 |
2010年 | 26篇 |
2009年 | 31篇 |
2008年 | 53篇 |
2007年 | 73篇 |
2006年 | 38篇 |
2005年 | 34篇 |
2004年 | 27篇 |
2003年 | 23篇 |
2002年 | 32篇 |
2001年 | 22篇 |
2000年 | 27篇 |
1999年 | 11篇 |
1998年 | 26篇 |
1997年 | 27篇 |
1996年 | 25篇 |
1995年 | 18篇 |
1994年 | 18篇 |
1993年 | 10篇 |
1992年 | 5篇 |
1991年 | 7篇 |
1990年 | 17篇 |
1989年 | 17篇 |
1988年 | 16篇 |
1987年 | 13篇 |
1986年 | 12篇 |
1985年 | 17篇 |
1984年 | 4篇 |
1983年 | 11篇 |
1982年 | 11篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1978年 | 7篇 |
1977年 | 4篇 |
1976年 | 5篇 |
1975年 | 7篇 |
排序方式: 共有852条查询结果,搜索用时 31 毫秒
1.
Megumi Oshima Meg J. Jardine Rajiv Agarwal George Bakris Christopher P. Cannon David M. Charytan Dick de Zeeuw Robert Edwards Tom Greene Adeera Levin Soo Kun Lim Kenneth W. Mahaffey Bruce Neal Carol Pollock Norman Rosenthal David C. Wheeler Hong Zhang Bernard Zinman Hiddo J.L. Heerspink 《Kidney international》2021,99(4):999-1009
2.
Cytokine networks in destructive periodontal disease 总被引:1,自引:0,他引:1
GL Howells 《Oral diseases》1995,1(4):266-270
BACKGROUND Cytokines are important regulatory proteins, produced by activated cells, which act by binding high affinity cell surface receptors. They are involved in almost all aspects of cell biology and form interacting networks, with cascades of sequential cell activation. They often show overlapping activities ( redundancy ) or the same cytokine may have a variety of different effects (pleiotropy). In excess, certain cytokines are damaging and proinflammatory. Tumour necrosis factor a (TNFα) and interleukin-I (IL-I) are markedly proinflammatory, inducing bone resorption, collagenase and prostaglandin E2 production.
OBJECTIVE: This paper focuses on the role of TNFa and IL-l in the cytokine networks of destructive chronic per-iodontitis; specifically their regulation by T cell cytokines, receptor antagonists and inhibitory soluble forms of the IL-l and TNF receptors.
CONCLUSION: A hypothesis is proposed that destructive periodontal disease may be due to disregulation of these inhibitors, rather than an overproduction of IL-l and TNFα per se. 相似文献
OBJECTIVE: This paper focuses on the role of TNFa and IL-l in the cytokine networks of destructive chronic per-iodontitis; specifically their regulation by T cell cytokines, receptor antagonists and inhibitory soluble forms of the IL-l and TNF receptors.
CONCLUSION: A hypothesis is proposed that destructive periodontal disease may be due to disregulation of these inhibitors, rather than an overproduction of IL-l and TNFα per se. 相似文献
3.
A perfluorocarbon blood substitute, Fluosol, is undergoing clinical trials as an adjunct to chemotherapy. The adverse effects associated with its administration have been postulated to result from complement activation. When gel electrophoresis and Western blotting of Fluosol are used after its incubation with serum, activated C3 and factors Bb and H are bound to the Fluosol particles in a time-dependent fashion, which suggests that complement activation with Fluosol, as does that with zymosan, occurs on the surface of the particles. Paradoxically, it is found, both by the measurement of Fluosol-bound C3d and by fluid-phase C5a, that lower concentrations of Fluosol cause greater amounts of complement activation, which suggests a complex interaction of activators and inhibitors that changes as the available surface area is decreased. Studies performed with bystander red cell-bound C3d demonstrated in vivo complement activation occurring in six patients receiving Fluosol as an adjunct to chemotherapy for colon cancer. In two patients, there was a marked increase in red cell-bound C3d after Fluosol infusion; these two patients also developed adverse reactions during Fluosol infusion. These studies suggest that the Fluosol surface plays a major role in the initiation and regulation of complement activation that is seen during Fluosol infusion. 相似文献
4.
贞芪扶正颗粒和复方阿胶浆干预再生障碍性贫血模型小鼠外周血及骨髓象的变化 总被引:2,自引:1,他引:2
目的:观察贞芪扶正颗粒和复方阿胶浆对苯油溶液致小鼠再生障碍性贫血模型的疗效。方法:实验于2005-06/09在河南中医学院药理实验室完成。①选用昆明种成年雄性小鼠90只。按随机数字表法将小鼠分为9组,每组10只:大、中、小剂量贞芪扶正颗粒组:按15,10,5g/kg剂量灌服贞芪扶正颗粒混悬液(主要成分:黄芪、女贞子;甘肃扶正药业科技股份有限公司生产;批号040803,15g/袋)。大、中、小剂量复方阿胶浆组:分别按10,20,30mL/kg剂量灌胃复方阿胶浆(主要成分:阿胶、熟地黄、党参、山楂、人参、蔗糖;山东东阿阿胶股份有限公司生产,批号050446,250mL/瓶),司坦唑醇组:按4mg/kg剂量灌胃司坦唑醇混悬液(司坦唑醇片,广西南宁百会药业集团有限公司生产,批号050306,30mg/片)。空白组和模型组:灌胃同体积的生理盐水(20mL/kg)。每天给药1次,连续给药14d。除空白组外,其余组小鼠皮下注射体积分数0.25苯的玉米油溶液4mL/kg复制苯油溶液致小鼠再生障碍性贫血模型,空白组皮下注射同体积玉米油。②各组小鼠分别于末次给药后24h,进行血常规检测。取右侧股骨,冲出骨髓细胞,采用BI-2000医学图像分析仪计数骨髓有核细胞数。③计量资料符合正态分布、方差齐者用t检验;方差不齐者用t’检验。结果:小鼠90只均进入结果分析。①血细胞测定结果比较:模型组小鼠血红细胞、白细胞、血小板计数和血红蛋白水平明显低于空白组(t=3.39~11.89,P<0.01)。司坦唑醇组3项血细胞计数和血红蛋白水平明显高于模型组(t=4.94~6.73,P<0.01)。大、中剂量贞芪扶正颗粒组和各剂量复方阿胶浆组血白细胞计数明显高于模型组(t=2.32~3.03,P<0.05 ̄0.01)。中剂量贞芪扶正颗粒组和各剂量复方阿胶浆组小鼠血红细胞计数明显高于模型组(t=2.15~4.84,P<0.05 ̄0.01)。大、中剂量贞芪扶正颗粒组和各剂量复方阿胶浆组血红蛋白水平明显高于模型组(t=2.33~4.45,P<0.05 ̄0.01)。大、中剂量贞芪扶正颗粒组和各剂量复方阿胶浆组血小板计数明显高于模型组(t=4.06~6.24,P<0.01)。②骨髓有核细胞数:模型组明显低于空白组(t=8.99,P<0.01)。司坦唑醇组、中剂量贞芪扶正颗粒组和小剂量复方阿胶浆组明显高于模型组(t=2.39~2.82,P<0.05)。结论:贞芪扶正颗粒、复方阿胶浆对皮下注射苯所致小鼠再生障碍性贫血模型血细胞状况及骨髓象均有较好的改善作用,以贞芪扶正颗粒有较为明显的剂量依赖关系。 相似文献
5.
Buse JB Ginsberg HN Bakris GL Clark NG Costa F Eckel R Fonseca V Gerstein HC Grundy S Nesto RW Pignone MP Plutzky J Porte D Redberg R Stitzel KF Stone NJ;American Heart Association;American Diabetes Association 《Diabetes care》2007,30(1):162-172
The American Heart Association (AHA) and the American Diabetes Association (ADA) have each published guidelines for cardiovascular disease prevention: the ADA has issued separate recommendations for each of the cardiovascular risk factors in patients with diabetes, and the AHA has shaped primary and secondary guidelines that extend to patients with diabetes. This statement will attempt to harmonize the recommendations of both organizations where possible but will recognize areas in which AHA and ADA recommendations differ. 相似文献
6.
William T. Cefalu Andrew J.M. Boulton William V. Tamborlane Robert G. Moses Derek LeRoith Eddie L. Greene Frank B. Hu George Bakris Judith Wylie-Rosett Julio Rosenstock Katie Weinger Lawrence Blonde Mary de Groot Matthew C. Riddle Robert Henry Sherita Hill Golden Stephen Rich Lyn Reynolds 《Diabetes care》2015,38(7):1177-1180
7.
Both microalbuminuria and insulin resistance are present at some stage in the natural history of non-insulin-dependent diabetes mellitus (NIDDM). Microalbuminuria predicts both progression to endstage renal disease and an increase in cardiovascular mortality compared to diabetic patients without microalbuminuria. Conversely, microalbuminuria is not a strong predictor of either renal or cardiovascular mortality in hypertensive nondiabetic subjects. This difference in risk may relate to the presence of glycated albumin in patients with diabetes. Glycation of albumin occurs because of persistent hyperglycemia. Glycated albumin is directly toxic to both renal and vascular tissue through stimulation of reactive oxygen species by both renal and immune protective cells. Blunting the rise in microalbuminuria with either aggressive blood glucose control or angiotensin-converting enzyme (ACE) inhibition, early in the course of the disease, markedly reduces renal mortality. In contrast to microalbuminuria, which is a reflection of renal injury, insulin resistance is a genetically determined problem that directly relates to peripheral glucose utilization. In most cases, insulin resistance is phenotypically expressed as diabetes as a result of environmental factors such as obesity. Insulin resistance is associated with an increased risk for development of both hypertension and NIDDM as well as atherosclerosis. Diabetic or hypertensive subjects with insulin resistance have an increased risk of cardiovascular but not renal mortality. Sustained weight loss is the best way to reduce insulin resistance and arterial pressure. Additionally, blockers, more than other antihypertensive agents reduce insulin resistance. This class of drugs, however, has not been shown to reduce either microalbuminuria or overall cardio-renal mortality. 相似文献
8.
9.
10.
SYMPLICITY HTN-3 was a pivotal moment for renal denervation as a treatment option for resistant hypertension. Prior unblinded studies were called into question given the negative results of the first sham-controlled trial of renal denervation. Reevaluation of the renal denervation procedure demonstrated that a more precise approach was needed to adequately denervate the kidney. This new approach has been implemented in two ongoing clinical trials, one on and one off medications to assess the new procedure’s efficacy and safety. These and other ongoing trials will be discussed in the context of older studies in this field. We focus on novel findings published following the release of SYMPLICITY HTN-3 data in early 2014 and look to the future of renal denervation in the treatment of primary hypertension. 相似文献